Table 3.
Logistic regression analysis results.
| Variables tested in the logistic regression analysis | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICC vs. non-cancer (n = 228) | Cancer stage (n = 128) | Promoter methylation | |||||||||||
| RARB | CADM1 | DAPKI | PAXI | ||||||||||
| OR (95% CI) | P-value | χ2 | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | ||
| Factors | RARB | 46.87 (9.61–228.54) | <0.001 | 17.32 | 0.002 | – | – | – | – | ||||
| CADM | 4.64 (1.89–11.35) | 0.001 | 12.68 | 0.013 | – | – | – | – | |||||
| DAPKI | 4.21 (1.69–10.49) | 0.002 | 5.09 | 0.279 | – | – | – | – | |||||
| PAXI | 10.04 (2.03–49.67) | 0.005 | 5.21 | 0.267 | – | – | – | – | |||||
| HIV status | 5.52 (1.23–24.79) | 0.026 | 19.93 | 0.001 | 1.53 (0.52–4.47) | 0.437 | 0.73 (0.31–1.74) | 0.480 | 1.15 (0.52–2.55) | 0.730 | 1.95 (0.34–11.20) | 0.455 | |
| HPV-16 | N/A* | 0.82 | 0.845 | 0.00 (0.00–0.00) | 0.999 | 1.79 (0.33–9.77) | 0.500 | 1.15 (0.26–5.10) | 0.854 | 10.48 (0.76–144.01) | 0.079 | ||
| HPV-18 | N/A* | 0.95 | 0.814 | 2.58 (0.29–22.94) | 0.395 | 1.62 (0.42–6.33) | 0.485 | 0.44 (0.15–1.33) | 0.147 | 2.79 (0.18–42.96) | 0.463 | ||
| Other hr-HPV | N/A* | 4.91 | 0.179 | 1.13 (0.20–6.41) | 0.888 | 2.40 (0.52–11.09) | 0.262 | 2.50 (0.79–7.86) | 0.118 | 1.51 (0.13–18.09) | 0.746 | ||
| Age | N/A* | 1.49 | 0.684 | 1.12 (1.01–1.26) | 0.037 | 1.02 (0.96–1.08) | 0.532 | 1.05 (1.00–1.10) | 0.040 | 1.02 (0.93–1.12) | 0.625 | ||
HIV, human immunodeficiency virus; HPV, human papillomavirus; hr, high risk; ICC, invasive cervical cancer; OR, odds ratio; CI, confidence interval; χ2, chi square value; N/A, not applicable.
*
Genotypes available only for ICC specimens.
Sample sizes differ slightly between analyses because of missing values and/or efficiency of molecular test.